RXRX
NASDAQRecursion Pharmaceuticals Inc.
Price$2.94-0.03 (-1.01%)
12:45 PM07:45 PM
News · 26 weeks80+10%
2026-01-182026-07-12
Mix3990d
- Insider23(59%)
- Other7(18%)
- SEC Filings6(15%)
- Leadership2(5%)
- Earnings1(3%)
Latest news
25 items- INSIDERDirector Borgeson Blake sold $158,500 worth of shares (40,000 units at $3.96) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 6,218,287 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Dar Zavain was granted 5,109 shares, increasing direct ownership by 2% to 240,764 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Li Dean Y was granted 3,747 shares, increasing direct ownership by 0.25% to 1,473,329 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- PRA Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsIssued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications expanding beyond oncology.USA News Group News CommentaryNEW YORK, June 30, 2026 /CNW/ -- Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a recent update from GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company built around its proprietary natural
- INSIDERDirector Borgeson Blake was granted 88,424 shares, increasing direct ownership by 1% to 6,258,287 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Hershberg Robert was granted 88,424 shares, increasing direct ownership by 120% to 162,156 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Michor Franziska was granted 88,424 shares, increasing direct ownership by 70% to 215,477 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Sun Elaine D was granted 88,424 shares, increasing direct ownership by 186% to 135,981 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Dar Zavain was granted 88,424 shares, increasing direct ownership by 60% to 235,655 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Bumpus Namandje was granted 88,424 shares and sold $12,602 worth of shares (3,963 units at $3.18) as part of a pre-agreed trading plan, increasing direct ownership by 196% to 127,632 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Li Dean Y was granted 88,424 shares, increasing direct ownership by 6% to 1,469,582 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SECRecursion Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- INSIDERChief Financial Officer Taylor Ben R covered exercise/tax liability with 5,396 shares, decreasing direct ownership by 0.49% to 1,101,876 units (SEC Form 4) (tax withholding)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- PRThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItIssued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually
- INSIDERDirector Gibson Christopher converted options into 40,000 shares and sold $144,800 worth of shares (40,000 units at $3.62) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERCEO and President Khan Najat sold $84,459 worth of shares (23,588 units at $3.58) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,175,796 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Bumpus Namandje sold $15,526 worth of shares (4,386 units at $3.54) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 43,171 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Borgeson Blake sold $110,400 worth of shares (30,000 units at $3.68) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,169,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- PRRecursion to Participate in Upcoming Investor ConferencesSalt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncolog
- PRRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesSalt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the "2024 Plan"). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4). Each inducement RSU
- INSIDERDirector Gibson Christopher converted options into 40,000 shares and sold $123,200 worth of shares (40,000 units at $3.08) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERCEO and President Khan Najat covered exercise/tax liability with 62,701 shares, decreasing direct ownership by 3% to 2,199,384 units (SEC Form 4) (for withholding tax)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERChief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,070,494 units (SEC Form 4) to cover withholding tax4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Gibson Christopher covered exercise/tax liability with 22,821 shares, decreasing direct ownership by 3% to 883,735 units (SEC Form 4) (for tax liability)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERChief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,107,272 units (SEC Form 4) to cover withholding tax4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
RXRX FAQ
7 questionsWhat does Recursion Pharmaceuticals Inc. do?
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is...Where does RXRX stock trade?
Recursion Pharmaceuticals Inc. (RXRX) is listed on NASDAQ.What sector and industry is RXRX in?
Recursion Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Recursion Pharmaceuticals Inc. go public?
Recursion Pharmaceuticals Inc. (RXRX) completed its IPO in 2021.What are analysts saying about RXRX?
Recursion Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $1100.00 price target on 2025-12-17.What companies are similar to RXRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare RXRX side-by-side with any of them on Quantisnow.How can I track RXRX on Quantisnow?
Quantisnow aggregates Recursion Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RXRX to receive live email and push alerts on every new disclosure.